


# Clinical Benchmark Comparison

## Benchmarking Discovery Leads Against 580+ Clinical-Stage Therapeutics

Contextualize lead candidates against successful commercial therapeutics. AbLead benchmarks project molecules across biophysical attributes, surface metrics, humanness, and immunogenicity against a curated database of 584 clinical-stage antibodies from Thera-SAbDab and Jain et al.



### CORE CAPABILITIES

- **584 Curated Clinical Reference Leads:** Curated clinical dataset from Thera-SAbDab and Jain et al., modeled with native Fab constant domains.
- **Multi-Dimensional Attribute Suite:** Benchmarks the AbLead project results values against those of the clinical set.
- **Percentile-Based Statistical Triage:** Categorizes values into Green (25th–75th benchmark window), Yellow (5th–25th / 75th–95th), Orange (atypical), and Red (out-of-bounds).
- **Overall KBC Score:** Evaluates the total rank order score of the AbLead project results against the clinical set.

### DEVELOPABILITY ADVANTAGE and IMPACT

- **Objective Drug-Likeness Validation:** Validates whether lead molecules fall within the proven developability envelope of approved commercial therapeutics.
- **Spot Atypical Red Flags Early:** Immediately identifies outlier attributes (e.g. unusually long CDR-H3, extreme charge, or excessive hydrophobicity).
- **Audit-Ready Reporting:** Exports benchmark comparison grids to Excel for inclusion in executive selection reviews, ELNs, and IND filings.
- **Data-Driven Candidate Ranking:** Provides clear rationale for choosing one lead candidate over another based on proven clinical biophysical ranges.

**The AbLead Advantage:** Rather than guessing whether a lead's developability metrics are acceptable, AbLead benchmarks every candidate against hundreds of clinical-stage antibodies to verify drug-likeness with hard statistical evidence. NOTE: While the clinical-stage antibody entries defining the ranges were successfully developed, some might not have been easy to develop. "Better" is better than "in range".

**Accelerate Your Antibody Lead Optimization and De-Risk Development**

Request a Live Demo: [ablead@ketchemconsulting.com](mailto:ablead@ketchemconsulting.com) | Explore Platform: [ablead.ketchemconsulting.com](https://ablead.ketchemconsulting.com)

Ketchem Biotherapeutics Consulting LLC • Developability by Design